Exploristics signs collaboration agreement with Renovion, using the cloud-based simulation platform KerusCloud for smarter clinical study design

Exploristics is pleased to announce today a collaboration with Renovion using Exploristics’ innovative study simulation software platform KerusCloud to establish a more efficient data-driven approach to study design and protocol development within Renovion’s clinical development programs.  Implemented across two projects, KerusCloud will deliver valuable quantitative insights to reduce the risks, costs, and duration of development programs in non cystic fibrosis bronchiectasis (NCFBRE) and chronic obstructive pulmonary disease (COPD).

Exploristics CEO Aiden Flynn said “We are delighted to be working with Renovion to harness KerusCloud’s powerful and realistic simulations to inform these important projects and ensure that their clinical trials are primed for success. With the KerusCloud software and our wraparound services, Renovion will be well-placed to exploit the unique data-driven insights that these tools can deliver to expedite the development of their ARINA-1 therapy.”

“In any clinical trial, starting with the ‘end in mind’ is the key to success,” said Dan Copeland CEO of Renovion.  “When the COPD Foundation introduced us to Exploristics, we were immediately impressed with the team and the way in which the KerusCloud platform can be used to model results to benefit not only this study but future studies.”

The COPD Foundation seeks to increase the number of therapies available for people with Bronchiectasis and COPD and one way to do that is by optimizing the design and efficiency of clinical trials and using the right endpoints.  ARINA-1 clinical development plan could benefit from collaborating with world class experts in the COPDF network.  Bruce Miller, PhD, Sr. Scientific Director COPD360Net commented “Renovion, Exploristics and the COPD Foundation’s collaboration builds on the COPD Foundation’s global network to ensure patient-centered, innovative and efficient clinical development of ARINA-1. This work extends the COPD Foundation’s ongoing work with Exploristics to support our Bronchiectasis and NTM Research Registry.”

About KerusCloud

KerusCloud is a uniquely powerful study simulation software platform that ensures clinical studies are suitably designed statistically from the outset to maximise their chances of success. To do this, KerusCloud creates highly realistic synthetic data sets (virtual populations) which are then used as a basis for generating thousands of study simulations that accurately mimic the complexity of real clinical studies. This allows researchers evaluate the performance of a wide variety of study designs and comprehensively analyse options in silico in minutes to efficiently choose the best options for real studies. For more information about KerusCloud, visit https://exploristics.com/kerus-cloud/.

About Exploristics

Exploristics is an enabling technology company that transforms clinical development for life science organisations with unique proprietary software and biostatistics services for planning, designing, and analysing clinical studies. For more information about Exploristics, visit www.exploristics.com or follow Exploristics on LinkedIn or Twitter.

About Renovion

Renovion is a clinical stage pharmaceutical company focused on developing ARINA-1, a novel nebulized therapy delivered to the lungs to treat pulmonary diseases. ARINA-1 clears mucus and reduces damaging inflammation in the airways to restore lung health. ARINA-1 is poised to start clinical trials in chronic inflammatory airways diseases, including non-cystic fibrosis (CF) bronchiectasis (NCFBE) and chronic obstructive pulmonary disease (COPD). The Renovion team has in-depth experience in drug development with extensive scientific expertise in chronic pulmonary conditions and inflammation. For more information on Renovion, visit https://www.renovion.com/.

About the COPD Foundation

The COPD Foundation is a not-for-profit organization established to improve the lives of people with COPD, bronchiectasis, and nontuberculous mycobacterial (NTM) lung disease through initiatives that expand services and speed innovations that will make treatment more effective and affordable. The Foundation does this through scientific research, education, advocacy, and awareness with the goal of disease prevention, slowed progression, and ultimately a cure. The COPD Foundation’s Digital Health and Therapeutics Accelerator Network (COPD360Net) supports the development and adoption of novel digital health tools, medical devices, and therapeutics that treat COPD, bronchiectasis, and NTM lung disease. COPD360Net consists of COPD Foundation accredited centers and practice-based research networks; experts in COPD and related lung diseases; relevant subject matter experts, including primary care physicians; clinical trial designers; health economists; and psychosocial experts.

To learn more, visit the COPD Foundation website or follow the Foundation on LinkedIn and Twitter.